StockpollyBeta
Get App
Popularity #3,602
MXCT · NASDAQ · Biotechnology

MaxCyte (MXCT)

Supplies ExPERT electroporation tools, consumables, licenses, and gene-editing assay services.

$1.25
vs last close+0.02 (+2.05%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue81611108910977107
Cost of revenue121122121232
Gross profit71410966976676
212222212019212117131316
Research & development667655665344
1415141414141414109911
Selling & marketing777766664433
General & administrative787887986567
Other expenses111111112101
Operating income−14−8−12−12−14−13−12−14−11−8−6−10
33332222−2−211
Interest income333322222211
Other non-operating income0−3−3−3−2−2−2−222−1−1
Income before tax−11−5−10−9−12−11−10−12−12−10−5−9
Net income from continuing operations−11−5−10−9−12−11−10−12−12−10−5−9
Net income−11−5−10−9−12−11−10−12−12−10−5−9
EPS, basic−$0.11−$0.05−$0.09−$0.09−$0.11−$0.10−$0.10−$0.12−$0.12−$0.09−$0.04−$0.08
EPS, diluted−$0.11−$0.05−$0.09−$0.09−$0.11−$0.10−$0.10−$0.12−$0.12−$0.09−$0.04−$0.08
Weighted average shares, basic103104104105105105106106106106107107
Weighted average shares, diluted103104104105105105106106106106107107
EBITDA−13−4−8−8−10−9−9−11−12−8−4−9
Depreciation & amortization111112111110
EBIT−14−5−10−9−12−11−10−12−12−10−5−9